Literature DB >> 16203624

ED-B fibronectin in non-small cell lung carcinoma.

Zia A Khan1, Julie Caurtero, Yousef P Barbin, Bosco M Chan, Shashi Uniyal, Subrata Chakrabarti.   

Abstract

Fibronectin (FN), a matrix glycoprotein, has been shown to undergo alternative splicing exclusively during organogenesis and tumorigenesis. One such splice variant, extradomain-B (ED-B) FN, is normally absent in normal adult tissues and is proposed to be a marker of tumoral angiogenesis. The present study was aimed at elucidating whether ED-B FN is expressed in non-small cell lung carcinomas and whether such aberrant expression correlates with tumoral angiogenesis. Frozen tissues from 28 non-small cell lung carcinomas (consisting of both squamous cell carcinomas and adenocarcinomas) along with paired normal tissue samples were collected from the tissue bank collection of the Department of Pathology, London Health Sciences Center, Canada. Frozen tissue specimens were subjected to RNA extraction and real time reverse transcriptase-polymerase chain reaction (RT-PCR) with respect to total and ED-B FN isoform expression. In addition, paraffin-embedded tissue sections from the same cases were collected for histological analysis using ED-B FN antibody. Tumor tissues were further stained with CD34 antibody and analyzed semiquantitatively for tumor microvessel density. The results demonstrate up-regulation of ED-B FN mRNA levels in lung tumor tissues as compared to paired normal tissues. Furthermore, ED-B FN expression was localized specifically to tumor cells and was found to correlate with tumor microvessel density. These findings provide evidence of possible involvement of ED-B FN in pulmonary tumoral angiogenesis. Furthermore, ED-B FN may potentially be used as a diagnostic marker and a target for antiangiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203624     DOI: 10.1080/01902140591007236

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  7 in total

1.  Targeting Fibronectin for Cancer Imaging and Therapy.

Authors:  Zheng Han; Zheng-Rong Lu
Journal:  J Mater Chem B       Date:  2016-12-01       Impact factor: 6.331

2.  Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.

Authors:  Shuai He; Jingjing Shi; HongHao Zhou; Qingling Li; Lanxiang Wu
Journal:  Cancer Gene Ther       Date:  2022-06-14       Impact factor: 5.987

Review 3.  Phage display screening of therapeutic peptide for cancer targeting and therapy.

Authors:  Phei Er Saw; Er-Wei Song
Journal:  Protein Cell       Date:  2019-05-28       Impact factor: 14.870

4.  Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.

Authors:  Phei Er Saw; Xiaoding Xu; Bo Ram Kang; Jungsul Lee; Yeo Song Lee; Chungyeul Kim; Hyungsin Kim; Shin-Hyuk Kang; Yoo Jin Na; Hong Joo Moon; Joo Han Kim; Youn-Kwan Park; Wonki Yoon; Jong Hyun Kim; Taek-Hyun Kwon; Chulhee Choi; Sangyong Jon; Kyuha Chong
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 5.  Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology.

Authors:  Francesca Di Modugno; Paola Nisticò; Sheila Spada; Annalisa Tocci
Journal:  J Exp Clin Cancer Res       Date:  2021-03-17

6.  Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Authors:  Relinde I Y Lieverse; Evert J Van Limbergen; Cary J G Oberije; Esther G C Troost; Sine R Hadrup; Anne-Marie C Dingemans; Lizza E L Hendriks; Franziska Eckert; Crispin Hiley; Christophe Dooms; Yolande Lievens; Monique C de Jong; Johan Bussink; Xavier Geets; Vincenzo Valentini; Giuliano Elia; Dario Neri; Charlotte Billiet; Amir Abdollahi; David Pasquier; Pierre Boisselier; Ala Yaromina; Dirk De Ruysscher; Ludwig J Dubois; Philippe Lambin
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

7.  Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells.

Authors:  Amita Vaidya; Helen Wang; Victoria Qian; Hannah Gilmore; Zheng-Rong Lu
Journal:  Cells       Date:  2020-08-03       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.